Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

BMC Cancer

Table 1 Covariate adjusted interaction tests between tamoxifen treatment efficacy according to recurrence-free interval and different cell proliferation markers analyzed as continuous linear variables. Co-variables included age (≥ 65 versus < 65), grade (grade 3 versus grade 1–2), tumor size (T3–4 versus T1-T2), HER2 status (positive versus negative), and PgR status (positive versus negative)

			Total follow-up	Follow-up truncated at 6 years^a
Variable	Variable values	N (events)	p-value	N (events)	p-value
Mitotic count square root	0 to 11	515 (124)	0.16	515 (92)	0.09
Cyclin D1 (continuous)	0 to 100%	432 (105)	0.96
Ki67 (continuous)	0 to 100	407 (99)	0.30
CCND1 probeset 1 log 2copy number ratio	−2.43 to 3.36	450 (103)	0.21
CCND1 probeset 2 log2 copy number ratio	−3.46 to 4.00	439 (102)	0.002

^aAnalysis performed for mitotic count only, since failure of proportional hazard assumption was observed

ISSN: 1471-2407